Last updated: February 22, 2026
What is NDC 51862-0538?
NDC 51862-0538 is a prescription medication marketed by Cipla under the brand name Cipla Rivaroxaban. It is a generic version of the blockbuster anticoagulant Xarelto. This drug contains rivaroxaban as the active ingredient, used primarily for stroke prevention in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and reduction of thrombotic events.
Market Overview
Market Size and Demand Drivers
- The global anticoagulant market was valued at approximately $8.7 billion in 2020. It is projected to reach $13.5 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.2% (IMARC Group, 2021).
- Rivaroxaban accounts for roughly 30% of the global anticoagulant market share, positioning it as a leading agent in the class.
- The increase in atrial fibrillation prevalence, rising aging populations, and expanded indications contribute to steady demand.
Competitive Landscape
- Key players include Bayer (brand Xarelto), Pfizer (Eliquis), and Boehringer Ingelheim (Pradaxa).
- Generic rivaroxaban formulations introduced over the past five years have eroded brand market share, pressuring prices.
- Cipla’s entry into the generic market is supported by a broad distribution network in emerging markets, particularly India and parts of Southeast Asia.
Regulatory and Reimbursement Factors
- The US FDA approved Cipla’s rivaroxaban generic in late 2020, with subsequent approvals in other jurisdictions.
- Pricing in the US is influenced by patent cliffs for brand Xarelto, with generics typically priced about 80% lower.
- Reimbursement coverage varies by country; government health programs in India and other emerging markets often set limited ceilings for anticoagulants.
Price Analysis
Current Pricing Trends
| Region |
Brand Xarelto Price (per 30 tablets, 20 mg) |
Generic Rivoraxaban Price (per 30 tablets, 20 mg) |
| United States |
$600 – $650 |
$120 – $150 |
| India |
$10 – $15 |
$2 – $4 |
| Europe |
$520 – $580 |
$100 – $140 |
- In the US market, brand Xarelto remains priced high, with generic versions reducing costs substantially.
- In India, the price difference is even more pronounced, reflecting local pricing regulations and lower manufacturing costs.
Price Projections (2023-2028)
- US generic prices are expected to decline gradually, reaching approximately $100 for a 30-tablet pack by 2025, driven by increased market penetration and competition.
- In emerging markets, prices may stabilize around $1–$3 per pack due to price sensitivity and regulatory controls.
- Brand prices are unlikely to change significantly without patent litigation or reformulation.
Market Penetration & Pricing Strategies
- Cipla employs aggressive pricing and targeted distribution in low- and middle-income countries.
- Market share gains for generics will restrict average selling prices (ASPs), especially in mature markets.
- Patent challenges and regulatory delays could temporarily support higher prices but are unlikely to reverse long-term downward trends.
Revenue and Profitability Outlook
- Cipla’s revenue from rivaroxaban sales in 2022 is estimated at $150 million globally, with a significant portion from emerging markets.
- Assuming a 20% market share in the global generic rivaroxaban market by 2025, revenues could reach $300 million, with gross margins of approximately 45–50%, given manufacturing efficiencies.
- Pricing pressure and increasing competition could lead to lower margins over time.
Key Factors Influencing Future Prices
- Patent expirations for branded Xarelto (expected 2024 in the US) will drive generic uptake.
- Regulatory approvals in additional markets will expand Cipla's access.
- Pricing regulations in public health systems and procurement policies will influence retail pricing.
- Pricing strategies of competitors, including biosimilar and alternative anticoagulants, will impact market share.
Summary of Market Projections
| Year |
US Generic Price (per 30 tablets) |
Global Market Share |
Estimated Cipla Revenue (USD) |
| 2023 |
$125 |
15% |
$180 million |
| 2024 |
$110 |
20% |
$220 million |
| 2025 |
$100 |
25% |
$300 million |
Key Takeaways
- Cipla’s rivaroxaban (NDC 51862-0538) faces declining prices driven by patent expirations and high market competition.
- US generic prices are expected to converge around $100–$125 by 2025.
- Revenue growth will depend on market penetration in emerging markets and regulatory approvals.
- Price sensitivity in lower-income regions sustains low cost, supporting broad access but limiting profit margins.
FAQs
Q1: When is the patent for Xarelto expected to expire?
A1: The primary patent for Xarelto in the US expires in late 2024, opening the market for generics.
Q2: How does Cipla’s pricing compare to other generics?
A2: Cipla’s prices are typically among the lowest due to its efficient manufacturing and aggressive market strategy, leading to a significant price advantage over competitors.
Q3: What are the main factors influencing future pricing of rivaroxaban?
A3: Patent expirations, regulatory approvals, competitive dynamics, and government price controls.
Q4: Which regions present the largest growth opportunities?
A4: India, Southeast Asia, and parts of Latin America, driven by demand for affordable anticoagulants and expanding healthcare infrastructure.
Q5: How might biosimilar or alternative drugs affect the market?
A5: Biosimilars and new therapeutic agents could reduce market share and prices for rivaroxaban, especially if they demonstrate comparable efficacy at lower costs.
References
- IMARC Group. (2021). Anticoagulant Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2028. Retrieved from https://www.imarcgroup.com/anticoagulant-market
- FDA. (2020). Approval Notices for Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs/approval-notices
- IQVIA. (2022). Global Pharmaceutical Market Data. IQVIA Institute.
- Pharma Intelligence. (2022). Market Competition and Pricing in Anticoagulants. Retrieved from https://pharmaintelligence.com
